Investigating the anti-TNBC potential of new quinazoline-based PAK4 inhibitors: design, synthesis and biological evaluation.
Results validate 11j as a promising lead for TNBC therapy, especially in combination with EGFR-targeted agents.
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Results validate 11j as a promising lead for TNBC therapy, especially in combination with EGFR-targeted agents.
Background: Cyclin-dependent kinase 4 (CDK4) is a key regulator of cell-cycle progression and an established therapeutic target for breast cancer. Although the unique architecture of its ATP-binding site has enabled the development of highly selective inhibitors, the emergence of acquired resistance highlights the need...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.